688076 Jiangsu Sinopep-Allsino Biopharmaceutical
- 56.49
- -0.66-1.15%
Jiangsu Sinopep-Allsino Biopharmaceutical News
We Think Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Nootech Biotech (688076.SH): Polypeptide products do not fall within the scope of synthetic biology
Gelonghui, May 16丨Nuotai Biotech (688076.SH) said on an interactive platform that the company's peptide products do not fall within the scope of synthetic biology.
Nootech Biotech (688076.SH): 66.8098 million restricted shares were lifted on May 20
Gelonghui, May 10, 丨 Nuotai Biotech (688076.SH) announced that the total number of shares in circulation during the current stock listing was 66.8098 million shares. The stock listing and circulation date is May 20, 2024.
Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Profits May Not Reveal Underlying Issues
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) robust recent earnings didn't do much to move the stock. However the statutory profit number doesn't tell the whole story, and we h
Nootech Biotech (688076.SH): Net profit of 66.326,800 yuan in the first quarter increased 215.65% year-on-year
Gelonghui, April 22丨Nuotai Biotech (688076.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 356 million yuan, up 71.02% year on year; net profit attributable to shareholders of listed companies was 66.368 million yuan, up 215.65% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 65.3985 million yuan, up 179.69% year on year; basic earnings per share were 0.31 yuan.
Is There An Opportunity With Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) 22% Undervaluation?
Key Insights The projected fair value for Jiangsu Sinopep-Allsino Biopharmaceutical is CN¥65.49 based on 2 Stage Free Cash Flow to Equity Jiangsu Sinopep-Allsino Biopharmaceutical's CN¥51.01 share p
Nootech Biotech (688076.SH) posted an advance increase. Net profit for the first quarter is expected to be 55 million yuan to 70 million yuan, a year-on-year increase of 161.74% to 233.13%
Nootech Biotech (688076.SH) issued an announcement. According to preliminary estimates by the finance department, the company's first quarter of 2024...
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) has had a great run on the share market with its stock up by a significant 38% over the last three months. Given that stock prices are usually
Starlink Management, a shareholder of Nordtech Biotech (688076.SH), reduced its holdings by a total of 74,100 shares, and the reduction period expired
Zhitong Finance App News, Nuotai Biotech (688076.SH) issued an announcement. The company recently received a “Notice of Stock Reduction Results” from the shareholder Jiande Xinglian Enterprise Management Co., Ltd. (hereinafter referred to as “Starlink Management”). The holdings reduction plan has expired. During the holdings reduction plan period, Starlink Management has reduced its holdings of the company's shares by a total of 74,100 shares, accounting for 0.03% of the total share capital.
Earnings Not Telling The Story For Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (SHSE:688076) After Shares Rise 26%
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (SHSE:688076) shares have had a really impressive month, gaining 26% after a shaky period beforehand. Looking back a bit further, it's encouraging to see
Dongguan Securities: The market size of peptide drugs with remarkable curative effects in the field of chronic diseases is expected to continue to increase
The market size of peptide drugs represented by GLP-1 drugs is rapidly expanding.
Nootech Biotech (688076.SH): Net profit increased 24.95% year-on-year in 2023
Gelonghui, Feb. 23 | Nuotai Biotech (688076.SH) announced its 2023 annual performance report. In 2023, the company achieved operating income of 103,56498 million yuan, an increase of 59.01% over the same period of the previous year; achieved operating profit of 189.067 million yuan, an increase of 51.43% over the same period of the previous year; realized a total profit of 170.237 million yuan, an increase of 38.05% over the same period last year; achieved net profit attributable to the parent company Deductions from company owners
Boji Pharmaceuticals (300404.SZ): Signed a technical service (contract) contract with Nootech
Glonghui, Feb. 19, 丨 Boji Pharmaceutical (300404.SZ) announced that on February 19, 2024, Boji Pharmaceutical Technology Co., Ltd. (“Boji Pharmaceutical”, “Company”, “Party B”) and Jiangsu Nuotai Aoseno Biopharmaceutical Co., Ltd. (“Nootai Biotech”, “Party A”) signed a “Technical Service (Entrusted) Contract” with a total contract amount of RMB 107.65 million (tax included). The contract agreed that Nootai Biotech would entrust Boji Pharmaceuticals to provide clinical research services for “simeglutide injection”.
Private Companies Among Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.'s (SHSE:688076) Largest Stockholders and Were Hit After Last Week's 4.8% Price Drop
Key Insights The considerable ownership by private companies in Sinopep-Allsino Bio PharmaceuticalLtd indicates that they collectively have a greater say in management and business strategy 50% of t
Nootech Biotech (688076.SH): Added certification of Zhang Yu and Liu Ting as core technicians
Nootech Biotech (688076.SH) issued an announcement. Gu Haitao, the company's deputy general manager and core technician, and core technology...
Fangzheng Securities: Wegovy (simeglutide) sales soared, and the GLP-1 related industry chain will expand more rapidly
The Zhitong Finance App learned that Fangzheng Securities released a research report saying that on January 31, 2023, Novo Nordisk released its 2023 financial report with revenue of US$33.7 billion. The total sales of the three Simeglutide products were US$21.157 billion, and the reduced Wegovy had sales of US$4.548 billion, an increase of 407% over the previous year. The domestic launch of simeglutide oral tablets is expected to drive the development of relevant industrial chain enterprises in China. API layout companies recommend focusing on Nootai Biotech (688076.SH), etc. It is recommended to focus on innovative domestic pharmaceutical companies that are deploying GLP-1 targets, such as Hengrui Pharmaceutical (60027)
Nootech Biotech (688076.SH): “Nootech Bonds Transfer” will be listed and traded on January 18
According to the Zhitong Finance App, Nootech Biotech (688076.SH) announced that the company's 434 million yuan convertible corporate bond will be listed and traded on the Shanghai Stock Exchange on January 18, 2024. The convertible corporate bond securities are called “Nootai Convertible Bonds” for short, and the stock code is “118046.”
These 4 Measures Indicate That Sinopep-Allsino Bio PharmaceuticalLtd (SHSE:688076) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Nootech Biotech (688076.SH): Wholly-owned subsidiary re-certified as a high-tech enterprise
Gelonghui, January 12丨Nuotai Biotech (688076.SH) announced that its wholly-owned subsidiary Hangzhou Ausainuo Biotechnology Co., Ltd. recently received the “High-tech Enterprise Certificate” jointly issued by the Zhejiang Provincial Department of Science and Technology, the Zhejiang Provincial Department of Finance, and the Zhejiang Taxation Bureau of the State Administration of Taxation. The issuance period is December 8, 2023, and the certificate is valid for three years. Auseno's adoption of the high-tech enterprise certification is a re-certification carried out after the expiration of the original “High-tech Enterprise Certificate”.
Nootech Biotech (688076.SH): 2023 net profit increased by 16.18% to 23.93%
Gelonghui, December 27丨Nuotai Biotech (688076.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, the company expects to achieve operating revenue of RMB 90,000,000 to RMB 1,000,000 in 2023. Compared with the same period of the previous year (statutory disclosure data), it will increase RMB 248.7083 million to RMB 348.7083 million, an increase of 38.19% to 53.54% over the previous year. Net profit attributable to owners of the parent company is expected to be between RMB 150,000,000 and RMB 16,000.0 in 2023
Analysis
Price Target
No Data
